Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
- PMID: 30797715
- PMCID: PMC6416167
- DOI: 10.1016/S1474-4422(18)30468-X
Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Abstract
Background: Brain and CNS cancers (collectively referred to as CNS cancers) are a source of mortality and morbidity for which diagnosis and treatment require extensive resource allocation and sophisticated diagnostic and therapeutic technology. Previous epidemiological studies are limited to specific geographical regions or time periods, making them difficult to compare on a global scale. In this analysis, we aimed to provide a comparable and comprehensive estimation of the global burden of brain cancer between 1990 and 2016.
Methods: We report means and 95% uncertainty intervals (UIs) for incidence, mortality, and disability-adjusted life-years (DALYs) estimates for CNS cancers (according to the International Classification of Diseases tenth revision: malignant neoplasm of meninges, malignant neoplasm of brain, and malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016. Data sources include vital registration and cancer registry data. Mortality was modelled using an ensemble model approach. Incidence was estimated by dividing the final mortality estimates by mortality to incidence ratios. DALYs were estimated by summing years of life lost and years lived with disability. Locations were grouped into quintiles based on the Socio-demographic Index (SDI), a summary indicator of income per capita, years of schooling, and total fertility rate.
Findings: In 2016, there were 330 000 (95% UI 299 000 to 349 000) incident cases of CNS cancer and 227 000 (205 000 to 241 000) deaths globally, and age-standardised incidence rates of CNS cancer increased globally by 17·3% (95% UI 11·4 to 26·9) between 1990 and 2016 (2016 age-standardised incidence rate 4·63 per 100 000 person-years [4·17 to 4·90]). The highest age-standardised incidence rate was in the highest quintile of SDI (6·91 [5·71 to 7·53]). Age-standardised incidence rates increased with each SDI quintile. East Asia was the region with the most incident cases of CNS cancer for both sexes in 2016 (108 000 [95% UI 98 000 to 122 000]), followed by western Europe (49 000 [37 000 to 54 000]), and south Asia (31 000 [29 000 to 37 000]). The top three countries with the highest number of incident cases were China, the USA, and India. CNS cancer was responsible for 7·7 million (95% UI 6·9 to 8·3) DALYs globally, a non-significant change in age-standardised DALY rate of -10·0% (-16·4 to 2·6) between 1990 and 2016. The age-standardised DALY rate decreased in the high SDI quintile (-10·0% [-27·1 to -0·1]) and high-middle SDI quintile (-10·5% [-18·4 to -1·4]) over time but increased in the low SDI quintile (22·5% [11·2 to 50·5]).
Interpretation: CNS cancer is responsible for substantial morbidity and mortality worldwide, and incidence increased between 1990 and 2016. Significant geographical and regional variation in the incidence of CNS cancer might be reflective of differences in diagnoses and reporting practices or unknown environmental and genetic risk factors. Future efforts are needed to analyse CNS cancer burden by subtype.
Funding: Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures




Comment in
-
Global consequences of malignant CNS tumours: a call to action.Lancet Neurol. 2019 Apr;18(4):324-325. doi: 10.1016/S1474-4422(19)30083-3. Epub 2019 Feb 21. Lancet Neurol. 2019. PMID: 30797716 No abstract available.
-
Role of neuropsychology in continuum of health care in neurological conditions.Neurol India. 2019 Mar-Apr;67(2):404-409. doi: 10.4103/0028-3886.258013. Neurol India. 2019. PMID: 31085848 No abstract available.
Similar articles
-
Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol. 2019 Apr;18(4):357-375. doi: 10.1016/S1474-4422(18)30454-X. Epub 2019 Feb 14. Lancet Neurol. 2019. PMID: 30773428 Free PMC article.
-
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642570 Free PMC article.
-
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16. Lancet Respir Med. 2017. PMID: 28822787 Free PMC article.
-
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Respir Med. 2021 Sep;9(9):1030-1049. doi: 10.1016/S2213-2600(21)00164-8. Epub 2021 Aug 16. Lancet Respir Med. 2021. PMID: 34411511 Free PMC article.
-
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.JAMA Oncol. 2022 Mar 1;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987. JAMA Oncol. 2022. PMID: 34967848 Free PMC article.
Cited by
-
Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?Int J Mol Sci. 2023 Oct 28;24(21):15701. doi: 10.3390/ijms242115701. Int J Mol Sci. 2023. PMID: 37958683 Free PMC article.
-
Progress in mimicking brain microenvironments to understand and treat neurological disorders.APL Bioeng. 2021 Apr 8;5(2):020902. doi: 10.1063/5.0043338. eCollection 2021 Jun. APL Bioeng. 2021. PMID: 33869984 Free PMC article.
-
The burden of brain and central nervous system cancers in Asia from 1990 to 2019 and its predicted level in the next twenty-five years : Burden and prediction model of CNS cancers in Asia.BMC Public Health. 2023 Dec 16;23(1):2522. doi: 10.1186/s12889-023-17467-w. BMC Public Health. 2023. PMID: 38104107 Free PMC article.
-
Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds.Cell Death Dis. 2024 Aug 15;15(8):592. doi: 10.1038/s41419-024-06971-5. Cell Death Dis. 2024. PMID: 39147758 Free PMC article.
-
MicroRNA-154: A Novel Candidate for Diagnosis and Therapy of Human Cancers.Onco Targets Ther. 2020 Jul 7;13:6603-6615. doi: 10.2147/OTT.S249268. eCollection 2020. Onco Targets Ther. 2020. PMID: 32753896 Free PMC article. Review.
References
-
- Global Burden of Disease Cancer Collaboration Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–548. - PMC - PubMed
-
- Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999;85:485–491. - PubMed
-
- Park KB, Johnson WD, Dempsey RJ. Global neurosurgery: the unmet need. World Neurosurg. 2016;88:32–35. - PubMed
-
- Bergen DC, Silberberg D. Nervous system disorders: a global epidemic. Arch Neurol. 2002;59:1194–1196. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical